Neurocrine Biosciences
Nasdaq NBIX · San Diego, CA
Works in Genetic & rare · Metabolic & endocrine · Neurology · Psychiatry · Renal & urogenital · Women's health
Neurocrine Biosciences is a clinical trial sponsor based in San Diego, CA, listed as Nasdaq NBIX. It has 18 active clinical trials with 4,661 planned participants, across 6 therapeutic areas. Since 2021 it has completed 37 trials and stopped 9 early.
Trial track record · since 2021
Financials · Nasdaq NBIX
Pipeline · 18 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
4 approved drug applications with a product on the market.
Questions about Neurocrine Biosciences
Neurocrine Biosciences is lead sponsor of 18 active clinical trials on ClinicalTrials.gov, with 4,661 planned participants, in Genetic & rare, Metabolic & endocrine, Neurology, Psychiatry and other areas. Since 2021 it has completed 37 trials and stopped 9 early.
Neurocrine Biosciences is based in San Diego, CA and is listed as Nasdaq NBIX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Neurocrine Biosciences; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-30.
Approve Suite is not affiliated with Neurocrine Biosciences.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.